USPTO ignites CRISPR/Cas9 patent battle

Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office (USPTO) agreed to initiate an interference proceeding.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Americas

Editas goes public amid CRISPR patent battle

10 February 2016 A biotechnology company that licenses a patent related to the gene-editing technology CRISPR/Cas9 has raised more than $94 million in its initial share offering.

Big Pharma

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

USPTO ignites CRISPR/Cas9 patent battle

More on this story

Editor's picks

Editor's picks

More features